Spain Women’s Health Market Size & Outlook, 2023-2030
Spain women’s health market, 2018-2030 (US$M)
Related Markets
Spain women’s health market highlights
- The Spain women’s health market generated a revenue of USD 1,434.7 million in 2023 and is expected to reach USD 2,209.0 million by 2030.
- The Spain market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 1,434.7 million |
| Market revenue in 2030 | USD 2,209.0 million |
| Growth rate | 6.4% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Spain accounted for 3.2% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany women’s health market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 3,031.4 million by 2030.
Contraceptives was the largest segment with a revenue share of 33.57% in 2023. Horizon Databook has segmented the Spain women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The market is becoming increasingly lucrative for women's health products, creating opportunities for market players. For instance, according to an NCBI article, the prevalence of menopausal symptoms and vulvovaginal atrophy ranges between 67% and 98% in Spanish women.
The increasing prevalence of targeted diseases and rising awareness among people are further boosting the market growth. For instance, according to the International Osteoporosis Foundation, the prevalence of osteoporosis is around 5.4% of the total population, out of these, around 79.2% of these are women patients.
Moreover, the number of fragility fractures in the country is expected to increase by more than 30% by 2034. Furthermore, according to World Bank, in 2022, Spain's women population aged 65 and above was around 5.46 million, which is further anticipated to increase the prevalence of targeted diseases.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain women’s health market size, by application, 2018-2030 (US$M)
Spain Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
